Form 4: Stephenson Fournier, PLLC Reports Reduced Ownership in Nanoviricides, Inc. Following New Securities Issuance

Stephenson Fournier, PLLC, a 10% owner of Nanoviricides, Inc. before a reverse split, has reported a decrease in their ownership percentage due to the company issuing new securities.

Summary

• Stephenson Fournier, PLLC, previously a 10% owner of Nanoviricides, Inc., has filed a Form 4 indicating a reduction in their ownership stake.
• This change is due to the issuance of new securities by Nanoviricides, which diluted the existing ownership percentages.
• The filing details the direct and indirect holdings of common stock by the reporting person, including shares held through Boniuk Interests Ltd and the Milton Boniuk IRA.
• The report also includes holdings of Series A Convertible Preferred Stock, which can be converted into common stock upon a change of control.
• The reporting person, Milton Boniuk, is represented by agents David Jon Boniuk and Debra Ann Boniuk, under a Durable Power of Attorney.

Sentiment

Score: 4

Explanation: The document indicates a dilution of ownership, which is generally viewed negatively by investors. However, it is a standard regulatory filing and does not indicate any major issues.

Negatives

• The reduction in ownership percentage for Stephenson Fournier, PLLC indicates a dilution of their stake due to the issuance of new securities by Nanoviricides.

Risks

• The issuance of new securities by Nanoviricides could lead to further dilution of existing shareholders' ownership.
• Changes in control could trigger the conversion of preferred stock, potentially impacting the share structure.

Industry Context

This filing is a standard disclosure for significant shareholders and is common in the biotech industry where companies often issue new securities for funding.

Comparison to Industry Standards

• Form 4 filings are a standard practice for reporting changes in beneficial ownership by insiders in publicly traded companies, including those in the biotech sector like Nanoviricides.
• The dilution of ownership due to new share issuance is a common occurrence in the biotech industry, especially for companies in the development stage that require capital for research and clinical trials.
• Other biotech companies such as Novavax and Moderna have also experienced similar ownership changes due to capital raising activities.

Stakeholder Impact

• Existing shareholders may experience a decrease in their ownership percentage due to the issuance of new securities.
• The dilution of ownership could potentially impact the share price.

Key Dates

Keywords

Nanoviricides, Ownership, Securities, Form 4, Dilution, Convertible Preferred Stock, Milton Boniuk, Durable Power of Attorney